Major Investor Quietly Boosts Stake in Neuronetics With Fresh Buy

New insider activity at Neuronetics ( (STIM) ) has taken place on August 17, 2026.

Significant shareholder Chernett Jorey has increased their stake in Neuronetics by purchasing 14,000 shares of the company’s stock in a recent transaction, with the total value of the buy amounting to $44,240. This move highlights continued investor interest in Neuronetics and adds a notable block of shares to Jorey’s holdings.

Neuronetics’ shares reacted to Q2 results that showed revenue and margins ahead of expectations, a sharply reduced net loss, and positive adjusted EBITDA, even as cash levels fell and losses persist. These metrics, along with tighter expense guidance and efforts to curb cash burn, underpin recent reassessments of the stock’s outlook.

Analyst views and AI-based assessments also reflect the strategic shift from a pure device model to a vertically integrated interventional psychiatry platform after the Greenbrook acquisition. Leadership changes consolidating financial and governance roles under a new CFO, plus operational initiatives to better monetize NeuroStar and scale Greenbrook clinics, are central to the rationale behind updated price targets and ratings.